Categories Earnings, Health Care

Earnings: Affimed cuts down losses in 2018

Affimed N.V. (AFMD), a clinical stage biopharmaceutical company that focuses on oncology drugs, Wednesday reported net losses that narrowed in 2018, helped by higher revenues. Net loss fell to €0.32 per share from €0.69 per share a year ago.

The bottom line was partially offset by a 64% hike in research and development expenses during this period, which was due to higher expenses for AFM13 and AFM11 clinical development activities, as well as early-stage development and discovery activities.

Image for representation (Photo by Drew Hays on Unsplash)

Revenues for the year rose to €23.7 million from €2 million in 2017.

CEO Dr. Adi Hoess said, “With our current financial resources, we believe we are well-positioned to achieve additional milestones in 2019 and beyond, including advancing our lead development candidate, AFM13, into a market registration-directed study and entering the clinic with AFM24, our second innate cell engager and a potential treatment for multiple solid tumor malignancies.”

Cash, cash equivalents and current financial assets jumped to €108.8 million as of December 31, 2018,
from €39.8 million during the same period last year.

AFMD shares ended its last trading session 1.75% in green on Tuesday.

READ: ONCONOVA THERAPEUTICS NARROWS LOSSES IN 2018

The stock got a major fillip when it announced in August last year a strategic deal with Genentech to develop and commercialize NK cell engager-based immunotherapeutics to treat multiple cancers. Genentech a member of Swiss multinational healthcare company Roche Group.

Buoyed by this news, the stock has more-than-doubled over the trailing 52 weeks. In the year-to-date period, Affimed shares have increased 25%, primarily helped by a 9% rally earlier this month when the German company said it would receive an undisclosed amount triggered by the achievement of a preclinical milestone under its ongoing strategic collaboration with Genentech.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

GameStop (GME) Earnings: Q1 loss narrows on 25% sales growth

Video game retailer GameStop Corp. (NYSE: GME), which has become the talk of the town after the unprecedented stock rally in recent weeks, reported a narrower loss for the first

Should you invest in Steel Dynamics (STLD) stock after 78% rally?

The steel industry managed to shrug off the pandemic blues earlier than expected as the recovery in industrial activity pushed up demand. With the vaccination drive and the government’s aggressive

Campbell Soup (CPB) Q3 Earnings: Key financials and quarterly highlights

Campbell Soup Company (NYSE: CPB) reported third-quarter 2021 earnings results today. Net sales decreased 11% year-over-year to $1.98 billion, as a result of lapping the demand surge at the onset

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top